Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
Author(s) -
Sara Pusceddu,
Natalie Prinzi,
Salvatore Tafuto,
Toni Ibrahim,
Angelina Filice,
Maria Pia Brizzi,
Francesco Panzuto,
Sergio Baldari,
Chiara Maria Grana,
Davide Campana,
Maria Vittoria Davì,
Dario Giuffrida,
Maria Chiara Zatelli,
Stefano Partelli,
Paola Razzore,
Riccardo Marconcini,
Sara Massironi,
Fabio Gelsomino,
Antongiulio Faggiano,
Elisa Giannetta,
Emilio Bajetta,
Franco Grimaldi,
Mauro Cives,
Fernando Cirillo,
Vittorio Perfetti,
Francesca Corti,
Claudio Ricci,
Luca Giacomelli,
Luca Porcu,
Massimo Di Maïo,
Ettore Seregni,
Marco Maccauro,
Secondo Lastoria,
Alberto Bongiovanni,
Annibale Versari,
Irene Persano,
Maria Rinzivillo,
Salvatore Antonio Pignata,
Paola Rocca,
Giuseppe Lamberti,
Sara Cingarlini,
Ivana Puliafito,
Maria Rosaria Ambrosio,
Isabella Zanata,
Alessandra Bracigliano,
Stefano Severi,
Francesca Spada,
Valentina Andreasi,
Roberta Modica,
Federica Scalorbi,
Massimo Milione,
Giovanna Sabella,
Jorgelina Coppa,
Riccardo Casadei,
Maria Di Bartolomeo,
Massimo Falconi,
Filippo de Braud
Publication year - 2022
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2022.0290
Subject(s) - radionuclide therapy , medicine , progression free survival , neuroendocrine tumors , oncology , hazard ratio , proportional hazards model , chemotherapy , targeted therapy , propensity score matching , retrospective cohort study , cancer , confidence interval
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom